

Index

Page references in **bold type** refer to illustrations.

- A**
- abortion, late
 - infections causing, 208–211
 - and wide cervical canal, 209, **210**
 - abscess
 - Bartholin gland, 104
 - breast, **229, 229**
 - labium, **79**
 - tubo-ovarian, 153–154
 - absorption tests, 35
 - aciclovir, 47
 - in herpes treatment, 90, 91
 - teratogenicity, 180
 - Acinetobacter anitratus*, 5
 - resistances, 162
 - acne
 - apocrine, 104
 - conglobata, 105, **105–165**
 - acquired immune deficiency syndrome (AIDS), 167, 175–178
 - and genital herpes, **90**
 - terminal stage, **177**
 - see also human immunodeficiency virus
 - Actinomyces israelii*, 16
 - actinomycetes, 5, 16
 - action sites, antibacterials, 38
 - acute phase proteins, 56–57
 - adnexa
 - and ascending infections, 147
 - conglomerate tumor, **149, 150, 152**
 - gonorrheal infection, 150
 - adnexitis, 148
 - adolescents, vaccination recommendations, 244
 - adults, vaccination recommendations, 244
 - aerobic bacteria, 3–4
 - amine testing, 58
 - aminoglycosides, 42
 - aminopenicillins, 40
 - amniotic fluid, pathogen detection, 37
 - amniotic infection syndrome (AIS), 214
 - amniotic sac, prolapse, 210, **211, 212**
 - amoxicillin, 40
 - amphotericin B, 49
 - ampicillin, 40
 - resistances, 162
 - anaerobic bacteria, 4
 - Anguillula stercoralis*, 236
 - anogenital region, skin care, 69
 - anthelmintic drugs, 50
 - antibacterials, 38–39
 - scope of application, 46
 - antibiotic treatment
 - broad-spectrum, and lactobacilli, 10
 - effects on intestinal flora, 46–47
 - in pregnancy and breast-feeding, 246
 - prophylaxis, 240–241
 - antibodies, cell-bound, 19
 - antibody-coated bacteria, 164
 - antibody function, 20
 - antibody production, *Candida*, 28
 - antibody testing, IgM, 34–35
 - anti-infectives, 38–52
 - antimycotic drugs, 48–49
 - antiparasitics, 50
 - antiseptics, 50–51
 - in trichomoniasis treatment, 118
 - apocrine acne, 104
 - appendicitis, 237
 - arenavirus, 192
 - arthritis, 237
 - Ascaris lumbricoides*, 234
 - ascending infections
 - after delivery, 217–218
 - internal genitals
 - course, 146
 - factors promoting, 146
 - prognosis, 146
 - in pregnancy, 168, **168**
 - aspergilloma, 167
 - aspergillosis, 167, **167**
 - Aspergillus fumigatus*, 8
 - Aspergillus niger*, and immunocompromised patients, 167
 - atrophic vaginitis, 128, **128, 129**
 - avidity determination, 35
 - azidothymidine (AZT), 47
 - AZT, see azidothymidine
- B**
- bacteria
 - aerobic, 3–4
 - anaerobic, 4
 - antibody-coated, 164
 - detection, 22–24
 - in vagina, 216
 - gastrointestinal tract, 12–13
 - Gram-negative, 3
 - Gram-positive, 3
 - gynecologically relevant, listed, 5–6
 - individual species and strains, 13–17
 - intestinal, and vaginitis, 127
 - morphology and sizes, 7
 - resistance, 162
 - species in vagina, 11
 - bacterial infections
 - in pregnancy, 193–208
 - prophylaxis, 240–241
 - bacterial vaginosis, 122–126, **124–125**
 - clinical picture, 124
 - diagnosis, 124–125
 - and hydrogen peroxide formation, 10
 - pathogenesis, 123–124
 - pathogens, 123
 - recurrent, 126
 - therapy, 126
 - transmission, 123–124
 - bacteriuria, 161
 - asymptomatic, 161
 - Bacteroides fragilis*, 5
 - Bacteroides* spp.
 - and pyometra, 148
 - and salpingitis, 149
 - barrier methods, HPV prophylaxis, 98–99
 - Bartholin cyst, 103, 104, **105**
 - Bartholin gland, 103
 - bartholinitis, **103, 103–104, 104**
 - diagnosis, 104
 - therapy, 104
 - Behçet syndrome, 108, **108**
 - vagina, **129, 129**
 - beta-lactam antibiotics, 39–42
 - biopsy, vulvar, 58, 61–62, **62–63**
 - birth, see delivery; pregnancy; puerperal; water birth
 - blastomycetes, 4
 - blood count, differential, 55
 - blood culture, 23
 - Bordetella pertussis*, 204
 - Borrelia*, and arthritis, 237
 - Borrelia* spp., and pregnancy, 197
 - borreliosis, in pregnancy, 196–198, **197**
 - diagnosis, 197–198
 - therapy, 198
 - botulism, 160
 - Bowen disease, 99, **99**
 - Bowenoid papulosis, 99
 - breast
 - erysipelas, 228–229, **229**
 - erythema, 228, **228**
 - furuncle, 229, **229**
 - inflammation, 224–231
 - breast-feeding
 - antibiotics during, 246
 - and mastitis, 226
 - bullous pemphigoid, in pregnancy, 181, **182**
 - buttocks, genital herpes, 87, **89**
- C**
- Calymmatobacterium granulomatis*, 233
 - Campylobacter* spp., 5, 16
 - and arthritis, 237
 - infection in pregnancy, 205
 - Candida albicans*
 - recurrent infection, 74–75
 - in vaginitis, 112, **113, 113–115, 114**
 - vulva, 69
 - and vulvitis, **67**
 - Candida glabrata*, 28, **28, 75**
 - in vaginitis, 114, **114**
 - vulvitis, 70
 - Candida* spp., 4
 - detection, 25, 26
 - and immunocompromised patients, 167
 - infection, 25, **27**
 - occurrence and clinical significance, 8
 - oral cavity, 13
 - tests, 29
 - candidiasis
 - chronic recurrent, therapy, 74–75
 - clinical picture, 69–70
 - diagnosis, 70, 72
 - differential diagnosis, 72–73
 - histology, 72, **73**
 - mammillae, 230, **230**
 - with pseudomycelia, 70, **72**
 - symptoms, 69
 - treatment, 73
 - vaginal, 112, **113, 113–115, 114**

- diagnosis, 114
therapy, 114
vulva, 69–75
vulvovaginal, differential diagnosis, 72–73, 74
- carbapenems, 42
- carbuncle, vulva, **77, 78, 78, 79**
- carcinoma
cervical, 144, 145, **145**
and HPV, 97
inflammatory mammary, 227–228, **228**
vulva, 108, **109**
- cardiovascular syphilis, 101
- catheter treatment, and infection, 239
- cefotaxime, 41
- cefuroxime, 41
- cell-bound antibodies, 19
- cellular defense system
nonspecific, 19
specific, 20–21
- Central European encephalitis (CEE), in pregnancy, 192–193
- cephalosporins, 40–42
- cerclage, for miscarriage prophylaxis, **211, 212, 212, 213**
- cervical canal, and late abortion, 209, **210**
- cervical carcinoma, 144, 145, **145**
and HPV, 97
- cervical polyp, in pregnancy, **209**
- cervicitis, 130–145
chlamydial, **135, 136**
clinical course and sequelae, **137**
clinical picture, 130–131, **132**
differential diagnosis, 145, **145**
gonococcal, **131, 137–138, 138, 139**
group A streptococci, 140, **140**
hyperplastic, **134**
other bacteria, 140
pathogen detection, 137
treatment, 137, 138
- cervix, 11, **11, 12**
Chlamydia infections, 131–138
condyloma, 142, 143, **143–144**
genital herpes, 140, **141–142, 142**
human papillomavirus (HPV), 142–144, **143–145**
infections, 130–145
primary syphilitic lesion, 139–140, **140**
- cesarean section, infections after, 221–222, **222**
- chancroid, 233
- chemoprophylaxis
HIV infection, 242
viral infections, 241
- chest radiography, in tuberculosis, 166
- chickenpox
and infection risk for newborn, 223
in pregnancy, **184, 184–186, 185, 186**
- childbed infections, 217–218
- children
and CMV infection in pregnancy, 182, **183, 184**
follow-up for syphilis, 195
and genital herpes in pregnancy, 179–180, 181
hepatitis A risk in pregnancy, 189
hepatitis B risk in pregnancy, 190
hepatitis C risk in pregnancy, 191
and herpes zoster, 186–187
immune disorders, 21
infection risk after birth, 223
infections during pregnancy, 168–169, **170**
premature, 213–214
primary genital herpes, 84, **86**
risk of borreliosis during pregnancy, 198
- risk of group B streptococcal infection, 206
- risk of toxoplasmosis during pregnancy, 199, **199, 200**
and syphilis infection in pregnancy, 194
vaccination recommendations, 244
and varicella in pregnancy, 185
see also fetus; infants; newborns
- Chlamydia* infection
and arthritis, 237
cervix, 131–138
classification, 132
clinical course and sequelae, **137**
diagnostic procedures, 136
and late-onset endometritis, 220
and peritonitis, 155
prevalence in Germany, **134**
treatment, **137**
- Chlamydia pneumoniae*, 132
- Chlamydia psittaci*, 132, 133
- Chlamydia trachomatis*, 5, 232
and ascending infections, 145
in cervicitis, **131**
classification, 132
clinical signs, **134, 134–135, 135**
and conglomerate tumor in adnexa, **149, 150, 152**
diagnosis, 135–137
and endometritis, **146**
and Fitz-Hugh–Curtis syndrome, 153, **153**
genital infections caused by, 133
and inflammatory conglomerate tumor, 153, 154
pathogenesis, 134
and salpingitis, 149
serotypes A–C, and trachoma, 133
serotypes D–K
diseases caused by, 135
and genital infections, 133–138
serotypes L1–L3, and lymphogranuloma venereum, 133
and subacute salpingitis, 151, **152**
transmission, 134
and tubo-ovarian abscess, 153, 154
- chlamydia spores, **27**
- chloramphenicol, 45
- chronic interstitial cystitis, 164–165
- cidofovir, 47
- Citrobacter diversus/freundii*, 5
- Citrobacter* spp., resistances, 162
- Clostridium perfringens/difficile*, 5
- Clostridium* spp., and gas gangrene infection, 160
- coagulase, and staphylococcal infection, 15
- coagulopathy, 57
- cocci, 7
- coitus, and cystitis, 161
- colitis, pseudomembranous, 46–47
- colpitis, 112
- colposcopy, 58
- complement fixation test (CFT), 31–32
- complement system, 18
- complications of infection, in pregnancy, 168
- condylomas
acuminate, 94–97, **95–96**
vagina, 115, **116**
and vulvitis, **67**
cervix, 142, 143, **143–144**
flat, in secondary syphilis, 101, **103**
- congenital varicella syndrome, 185
- conglomerate tumor
adnexa, **149, 150, 152**
inflammatory, 153–154
diagnosis, 154
- pathogenesis, 153
- pathogens, 154
therapy, 154
- contraception
and enzyme induction, 245
and urinary tract infection, 161
- Corynebacterium minutissimum*, 93
- Corynebacterium* spp., resistances, 162
- co-trimoxazole
drug exanthema, **110**
resistances, 162
- coxsackievirus, in pregnancy, 188
- C-reactive protein (CRP), 56, 57
- Credé prophylaxis, 242
- crust stage, genital herpes, 87, **89**
- Cryptococcus neoformans*, 8
- culture methods
bacteria, 24
fungi, 26, 28
viruses, 25
- cutaneous larva migrans, 236, **236**
- cyst, Bartholin gland, 103, 104, **105**
- cysticercus, 235
- cystitis, 161–163
chronic interstitial, 164–165
clinical picture, 161
diagnosis, 161–162, 163
pathogens, 162
therapy, 162–163
- cytomegalic inclusion disease, 181–182, **183**
- cytomegalovirus (CMV)
congenital infection, 183–184
infection during pregnancy, 183–184
and infection risk for newborn, 223
reactivation of infection in pregnancy, 184
- D**
- dalfopristin, 46
- defense systems, 18–21
- delivery, premature, infections causing, 208–211
- Demodex folliculorum*, 107
- dengue fever, in pregnancy, 216
- dermatitis, irritable, vulva, 109, **109, 110**
- dermatophytes, 75–76, **76**
- dermatosis, 112
- differential diagnosis, 232
- diagnosis of infections, 58–63
vagina and vulva, **112**
- direct agglutination (DA) test, toxoplasmosis, 200
- discharge
bubbly, in bacterial vaginosis, 124, **124**
microscopy, 58, **60–61, 61**
pH value, 58, **59**
- disinfection, preoperative, 239–240
- DNA analogs, 47
- DNA chips, 36
- Douglas pouch, abscess formation, 156
- drug eruption, local, 109–110, **110**
- drug fever, 54
- drug interactions, 245
- E**
- E. coli*, *see* *Escherichia coli*
- echovirus, in pregnancy, 188
- ectopia of portio, **131**
- EHEC, *see* enterohemorrhagic *Escherichia coli*
- ehrlichiosis, in pregnancy, 198
- empyema, Bartholin gland, 103
- endocervix, 11

- endometritis, 146, **146**, 220–221
in outpatients, 147, **147**
special forms, 147–148, **148**
- Enterobacter cloacae*, 5
resistances, 162
- Enterobacteriaceae*, 15–16
and cervicitis, 140
and inflammatory conglomerate tumor, 154
and septic shock, 158, 159
and tubo-ovarian abscess, 154
- Enterobius vermicularis*, 234
- enterococci, 5, 14
resistances, 162
- Enterococcus faecium*, 14
- enterohemorrhagic *Escherichia coli* (EHEC), 16
- enterotoxinogenic *Escherichia coli* (ETEC), 16
- enteroviruses, in pregnancy, 188
- enzyme immunoassay (EIA), 33–34
- enzyme induction, 245
- enzyme-linked immunosorbent assay (ELISA), 33–34
- episiotomy wound, infection, **208**
- Epstein–Barr virus infection, in pregnancy, 187
- erosive lichen planus, **110**, 110–111
- erosive vaginitis, 128, **129**
- eruption, local, 109–110, **110**
- erysipelas, 81, **82**
of breast, 228–229, **229**
- erythema, of breast, 228, **228**
- erythema infectiosum, in pregnancy, 173–175
clinical picture, 174
complications, 174
diagnosis, 174–175
exposure, 175
pathogen, 174
pathogenesis, 174
prophylaxis, 175
therapy, 175
- erythrasma
submammary folds, 94, **94**
vulva, 93–94, **94**
- erythrocyte sedimentation rate (ESR), 55–56
- Escherichia coli*, 5, 15–16
and amniotic infection syndrome, 214
and cervicitis, 140
and peritonitis, 155
and pregnancy, 208
resistances, 162
and salpingitis, 150
and septic shock, 158, 159
and subacute salpingitis, 151
urinary tract infection, 161
see also enterohemorrhagic; entero-toxinogenic
- ETEC, *see* enterotoxinogenic *Escherichia coli*
- Eubacterium*, 5
- exanthema
syphilitic, **102**
vulva, drug eruption, **110**
- eye infection, prophylaxis in newborns, 242
- F**
- factitious infections, 238, **238**
- factitious vulvitis, 238, **238**
- facultative pathogens, mycobacteria, 166
- famciclovir, 47
- fetus
and CMV infection in pregnancy, 182, **183**, 184
- and genital herpes in pregnancy, 179–180
- hepatitis A risk in pregnancy, 189
- hepatitis B risk in pregnancy, 190
- hepatitis C risk in pregnancy, 191
and herpes zoster, 186–187
- infections during pregnancy, 168–169, **170**
- premature membrane rupture, 212–214
- risk of borreliosis during pregnancy, 198
- risk of group B streptococci infection, 206
- risk of toxoplasmosis during pregnancy, 199, **199**, 200
- and syphilis infection in pregnancy, 194
and varicella in pregnancy, 185
see also children; infants; newborns
- fever, 54
and miscarriage, 222–223
in pregnancy, 215
- fifth disease, 173–175
- Fitz–Hugh–Curtis syndrome, 153, **153**
- flora, vaginal
normal, 2, 4, **9**, 10–11
normal vs. disturbed, 11
- flu, in pregnancy, 193
- fluoroquinolones, 44
- foscarnet, 47
- fosfomycin, 46
- fox den disease, 104
- fungal infections, 4
antimycotic drugs, 48
detection, 25–26
differential-diagnostic characteristics, 8
immunocompromised patients, 167
rare, treatment, 73
systemic treatment, 49
- fungi
morphology and sizes, **7**
swab preparation, 25, **27**
- furuncle, vulva, **77**, **78**, **78**, **79**
- Fusobacterium nucleatum*, 5
- G**
- ganciclovir, 47
- Gardnerella vaginalis*, 5, 122, 123, **125**
and pregnancy, 207
- gas gangrene infection, 160
- gastroenteritis, and infection risk for newborn, 223
- gastrointestinal tract bacteria, 12–13
- gene chips, diagnostic, 36
- genital herpes, 82–90
cervix, 140, **141–142**, 142
crust stage, 87, **89**
epidemiology, 82–83
and immune suppression, 87, **89**, **90**
infectivity, 82
pathogen, 82, 87
pathogenesis, 83
in pregnancy, **179**, 179–181, **181**
treatment, 180
primary, 83–87
in children, 84, **86**
clinical picture, 83–84, **84–86**
diagnosis, 86–87
therapy, 87
recurrent, 87–91
clinical picture, 87, **88–90**, 89
diagnosis, 90, 91
in pregnancy, 180–181
therapy, 90
transmission, 82, 83, 87
vagina, 115, **115**
and vulvitis, **67**
- genitals, internal, ascending infections, 145–160, **147**
- genital tuberculosis, 165–166, **166**
clinical picture, 165
diagnosis, 165–166
pathogenesis, 165
prophylaxis, 166
therapy, 166
in pregnancy, 166–167
transmission, 166
- genital warts, 94–97, **95–96**
clinical picture, 95, **95–96**, 97
diagnosis, 97–98
drugs, 48
therapy, 98
and vulvitis, **67**
- gentamicin, resistances, 162
- Geotrichum candidum*, 8
- German measles
pathogen, 169–170
in pregnancy, 169–172
- glandular fever, 187
- glycopeptides, 43
- gonococcal cervicitis, 137–138
- gonococci, 5, 7, *see* *Neisseria gonorrhoeae*
- gonorrhoea, 232
- Gram staining, bacterial species, 3, 5–6
- granular vaginitis, 129–130, **130**
- granulocytes, 19
- granuloma inguinale, 233
- granulomatous mastitis, 229, **229**
- gynecologic infections, 66–167
- H**
- Haemophilus ducreyi*, 5, 233
- Haemophilus influenzae*, 5
and amniotic infection syndrome, 214
- Haemophilus vaginalis*, 5
- helminthic infections, 234–236
- hemagglutination inhibition test, 32
- hemagglutination test, *Candida*, 29
- hematogenous infections, in pregnancy, 168, **168**
- hemolysis-in-gel test, 32–33
- hepatitis in pregnancy, 188–192
A, 188–189, 216
B, 189–191
and infection risk for newborn, 223
C, 191
and infection risk for newborn, 223
D, 191
E, 191–192
G, 192
types, 189
- hepatosplenomegaly, and CMV infection in pregnancy, 182
- herpes
genital, *see* genital herpes
neonatal, 180
- herpes gestationis, 181, **181**
- herpes glutealis, **89**
- herpes labialis, 86, **86**
and infection risk for newborn, 223
- herpes simplex virus (HSV), 82–91
and salpingitis, 149
vagina, 115, **115**
see also genital herpes
- herpesviruses
in pregnancy, 187
and vulvitis, 82
- herpes zoster
in pregnancy, 186–187, **187**
vulva, 91, **92**
- hidradenitis suppurativa, 104–105
- HIV, *see* human immunodeficiency virus

- HPV, *see* human papillomavirus
 HSV, *see* herpes simplex virus
 human herpesvirus type 6 (HHV-6), 187
 human immunodeficiency virus (HIV), 167, 175–178
 clinical picture, 177
 diagnosis, 177–178
 incubation time, 176
 and infection risk for newborn, 223
 pathogen, 175
 pathogenesis, 176
 professional exposure, 242
 prophylaxis during pregnancy, 178
 risk for gynecological patients, 177
 transmission, 176
 treatment in pregnancy, 178–179
 and viral chemoprophylaxis, 241
 viremia, 176
 virostatic drugs, 47–48
 human papillomavirus (HPV), 48
 and cervical carcinoma, 97
 cervix, 142–144, **143–145**
 high-risk, and tumor development, 97
 high-risk vs. low-risk, 94
 infections, 94–100
 prophylaxis, 98–99
 vagina, 115–116, **116**
 and vulvitis, **67**
 humoral defense systems
 nonspecific, 18
 specific, 19
 hydrogen peroxide formation, and bacterial vaginosis, 10
 hydrosalpinx, **149**, 150
 hyperimmune globulin treatment, 52
 in rubella, 173, 174
 and varicella, 186
 hyperkeratosis, and candidiasis, 72, **73**
 Hyphomycetes, 4
 hysterectomy, and infections, postoperative, 155
- I**
- IgA antibodies, 19
 IgD antibodies, 20
 IgE antibodies, 20
 IgG antibodies, 20
 IgM antibodies, 19
 IgM antibody testing, 34–35
 imidazole derivatives, 49
 immune responses, 53
 immune suppression, and genital herpes, 87, **89**, **90**
 immune system, 18
 disorders, 21
 immunocompromised patients, 167
 immunofluorescence tests (IFT), 33
 Candida, 29
 immunoglobulins, 19, 20, 51–52
 preparations, 52
 prophylaxis, 51–52
 therapy, 52
 immunoprophylaxis, viral infections, 241
 immunosorbent agglutination assay (ISAGA), toxoplasmosis, 201
 impetigo contagiosa, 81
 incontinence, urinary, 161
 indirect hemagglutination assay (IHA), toxoplasmosis, 201, **201**
 indwelling catheter, and infection, 239
 infants
 vaccination recommendations, 244
 see also children; fetus; newborns
 infection risks, 239
 infections
 ascending, internal genitals, 145–160, **147**
 vagina, 112–130
 infectious mononucleosis, 187
 inflammatory mammary carcinoma, 227–228, **228**
 influenza, in pregnancy, 193
 inguinal lymph nodes, swelling, in genital herpes, 83, **84**
 interferons, 18
 internal genitals, ascending infections, 145–160, **147**
 interstitial cystitis, chronic, 164–165
 intestinal bacteria, and vaginitis, 127
 intestinal flora, antibiotic effects, 46–47
 intestinal pathogens, and pregnancy, 208
 intravenous catheter, and infection, 239
 irritable vulvitis, 109, **110**
 itching
 and candidiasis, vulva, 69
 vulva, 68
- K**
- keratoangioma, 99, **99**
 kidney values, 57
Klebsiella, 16
 and septic shock, 158
Klebsiella pneumoniae, resistances, 162
Klebsiella pneumoniae/oxytoca, 5
- L**
- labor, induction, in amniotic infection syndrome, 214
 laboratory values, 55–57
 lactation, and antibiotic treatment, 246
 lactobacilli, 4, 5, **9**, 9–11
 and broad-spectrum antibiotics, 10
 morphology, different species, 10
 laparoscopy, salpingitis, subacute, 152
 larva migrans, cutaneous, 236, **236**
 latent infection, reactivation in pregnancy, 169
 leprosy, 166
 leukocytes, 55
 leukocytosis, 55
 leukopenia, 55
 lice, 50
 pubic, 106, **106–107**
 lichen planus, erosive, **110**, 110–111
 lincosamides, 43
 lipopeptides, 43
Listeria monocytogenes, 5
Listeria spp., and pregnancy, 195
 listeriosis, in pregnancy, 195–196, **196**
 diagnosis, 195–196
 prophylaxis, 196
 therapy, 196
 liver values, 57
 local drug eruption, 109–110, **110**
 lues, 100, 232
 in pregnancy, 193–195
 Lyme disease, in pregnancy, 196–198, **197**
 lymph nodes, inguinal, swelling, in genital herpes, 83, **84**, 85
 lymphocytic choriomeningitis (LCM), in pregnancy, 192
 lymphogranuloma venereum (LGV), 232–233
 and *Chlamydia trachomatis*, 133
 lysozymes, 18
- M**
- macrolides, 43
 macrophages, 19
 malabsorption, and antibiotic treatment, 246
 malaria, 29, 50
 in pregnancy, 202–203, 215–216
Malassezia furfur, 4
 mammary carcinoma, inflammatory, 227–228, **228**
 mammillae
 candidiasis, 230, **230**
 chronic redness, 231, **231**
 dermatitis, 229, **230**
 marsupialization, in Bartholinitis, 104
 mastitis, 224
 abscess-forming, 226
 and breast-feeding, 226
 chronic, in pregnancy with sarcoidosis, **230**, 230–231
 granulomatous, 229, **229**
 and infection risk for newborn, 223
 nonpuerperal, 226–227, **226–227**
 puerperal, 224–226
 tuberculous, 226
 measles, in pregnancy, 187–188
 methadone treatment, in pregnancy, 179
 methicillin-resistant *Staphylococcus aureus* (MRSA), 15
 microphages, 19
 microscopy, of discharge, 58, **60–61**, 61
 miscarriage
 and fever, 222–223
 infections causing, 208–211
 prophylaxis, **211**, 211–212
 mites, 50, 107, **107**
Mobiluncus, 5, 6, 123, **125**
 molds, 4
 molecular biology
 detection methods, 35–36
 and pathogen detection, 22
 mollusum contagiosum, 91, **91**
 monobactams, 42
 mononucleosis, infectious, 187
 mons pubis, mollusum contagiosum, 91, **91**
 MRSA, *see* methicillin-resistant *Staphylococcus aureus*
 mumps, in pregnancy, 188
 Munchausen syndrome, 238
 mycelial fungi, 4
 mycobacteria, diseases caused, 166
Mycobacterium avium/intracellulare complex, 165
Mycobacterium bovis, 165
Mycobacterium tuberculosis, 5, 165
Mycoplasma, vagina, 126–127
Mycoplasma genitalium, and subacute salpingitis, 151
Mycoplasma hominis, 5
- N**
- natamycin, 49
 natural killer cells, 19
 necrotic fasciitis, and puerperal sepsis, 218
Neisseria gonorrhoeae, 5, 6, 138, **138**
 and ascending infections, 145
 and salpingitis, 149
 treatment in salpingitis, 151
 neonatal herpes, 180
 neurosyphilis, 101
 neutralization test (NT), 33
 neutropenic patients, 167

- newborns
 and follow-up for syphilis, 195
 infection risk from mother, 223
 ocular prophylaxis, 242
 tuberculosis vaccination, 242–243
 see also children; fetus; infants
- nitroimidazoles, 44–45
- nits, 106, **106**
- nonnucleoside reverse transcriptase inhibitors (NNRTI), 47–48
- nonpuerperal mastitis, 226–227, **226–227**
- norfloxacin, resistances, 162
- nystatin, 49
- O**
- ophthalmia neonatorum, 242
- opsonization, 19
- oral cavity, flora, 13
- ovarian vein, thrombophlebitis, 221
- oxazolidinones, 44
- oxyurids, 234
- Oxyuris vermicularis*, 234
- P**
- Paget disease, 231, **231**
- papillomatosis, 99, **99**
 vagina, 116
- papillomavirus, see human papillomavirus
- papulosis, bowenoid, 99
- paramyxovirus, 188
- parvovirus B19, 174
 and arthritis, 237
- pathogens, 2–17
 detection, 22–37
 morphology and sizes, 7
- pelvic inflammatory disease (PID), 148
 and hydrosalpinx, **149**
- pelvioperitonitis, 156
- pelvis, small, thrombophlebitis, 156
- pemphigoid, 111
 bullous, in pregnancy, 181, **182**
- pemphigoid gestationis, 181
- pemphigus vulgaris, vulva, 111
- penicillins, 39–40
 and syphilis infection in pregnancy, 194
- peptococci, 6
- perihepatitis, 153, **153**
- perinatal varicella, mother, 185
- periparturient infections, 217–223
- peritonitis, 155–156
 clinical picture, 156
 diagnosis, 156
 pathogenesis, 156
 pathogens, 155–156
 therapy, 156
- pertussis, in pregnancy, 204
- Pfeiffer disease, 187
- phagocytes, 19
- phagocytosis, 19
- pharyngitis, in pregnancy, 203
- phthiriasis pubis, 106, **106–107**
- Phthirus pubis*, 106, **106**
- pH value of discharge, 58, **59**
- pinworms, 234, **234**
- pityriasis versicolor, 4
- plasma cell vaginitis, 119–120, **120–121**
- plasma cell vulvitis, 92, **93**
- Plasmodium falciparum*, and pregnancy, 202
- PMN elastase, 56–57
- pneumococci, 6, 237
- pneumonia, 237
 drug treatments, 237
 pathogens, 237
- podophyllotoxin, 48
- poliovirus, in pregnancy, 188
- polyenes, 49
- polymerase chain reaction (PCR), 25, 35–36
- polymorphonuclear (PMN) granulocytes, 56
- portio vaginalis
 ectopia, **11, 12, 131**
 hyperplasia, in pregnancy, **209**
- papillomavirus infection, 144
- postexposure prophylaxis (PEP), and HIV infection, 242
- postoperative infection, 160
- postpartum bacterial detection, 212, **213**
- postpartum infections, ascending, 217–218
- pregnancy
 antibiotics during, 246
 and antiretroviral treatment, 179
 bacterial infections, 193–208
 and bacterial vaginosis, 207–208
 borreliosis, 196–198, **197**
Campylobacter infection, 205
 cervical polyp, **209**
 and complicated UTIs, 164
 cytomegalic inclusion disease, 181–182, **183**
 and cytomegalovirus (CMV) infection, 183–184
 dengue fever, 216
 ehrlichiosis, 198
 enteroviruses, 188
 fever during, 215
 and genital herpes, **179, 179–181, 181**
 group A streptococcal infection, 203–204
 group B streptococcal infection, 205–207, **206**
 and hepatitis, 188–192
 A, 216
 types, 189
 herpes zoster infection, 186–187, **187**
 and HIV infection, 175–178
 induction of labor, in amniotic infection syndrome, 214
 infections after cesarean section, 221–222, **222**
 infections during, 168–216
 treatment, 169
 viral, 169–193, **170**
 influenza during, 193
 listeriosis, 195–196, **196**
 and malaria, 202–203, 215–216
 measles, 187–188
 mumps, 188
 pathogen detection in vagina, 216
 pertussis, 204
 and portio vaginalis hyperplasia, **209**
 prophylaxis against miscarriage, 211–212
 Q fever, 205
 rotavirus, 188
 salmonella infection, 204–205
 with sarcoidosis, and chronic mastitis, **230, 230–231**
 and scarlet fever, 203–204
 and syphilis, 193–195
 screening, 194–195
 toxoplasmosis, 198–202, **199**
 and trichomoniasis, 119, 215, **215**
 and tropical infections, 215–216
 and tuberculosis, 166–167
 and urinary tract infections, 161
 vaccination during, 243
 and varicella, **184, 184–186, 185, 186**
 whooping cough, 204
- premature delivery, infections causing, 208–211
- prenatal diagnosis, rubella, 172
- prenatal infections, detection, 36–37
- preoperative disinfection, 239–240
- prevention of infections, 239–246
- prolapse, amniotic sac, 210, **211, 212**
- properdin system, 18
- prophylaxis, antibiotic, 240–241
- propionibacteria, 6, 12
- protease inhibitors, 48
- Proteus mirabilis*, and urinary tract infection, 161
- Proteus* spp., 6
 resistances, 162
- protozoa, 4
 detection, 29
 morphology and sizes, 7
- pseudomembranous colitis, 46–47
- Pseudomonas aeruginosa*, 16
- Pseudomonas* spp., 6
 resistances, 162
- pseudomyces, 4, **27**
 and candidiasis, 70, **72**
- psoriasis vulgaris, vulva, 111, **111**
- puerperal infections, 217–223
- puerperal mastitis, 224–226
 clinical picture, 224, **224–225**
 pathogen, 224
 therapy, 225–226
 transmission, 224
- puerperal sepsis, 218–220, **219**
 clinical picture, 218
 diagnosis, 218–219
 epidemiology, 218
 prophylaxis, 220
 therapy, 219
- purulent vaginitis, 119–120, **120–121**
- pustules, in genital herpes, 83, **85, 87, 88**
- pyelonephritis, acute uncomplicated, 163
- pyoderma
 fingers, **81**
 vulva and surrounding areas, 76
- pyoderma fistulans, 104–105, **105**
- pyometra, 147–148, **148**
- pyrimidines, 49
- Q**
- Q fever, in pregnancy, 205
- Q–T interval, prolongation, 245
- quinupristin, 46
- R**
- radiography, chest, in tuberculosis, 166
- radioimmunoassay (RIA), 34
- reactivation of infection, in pregnancy, 169
- red halo, ulcers, in genital herpes, 83, **85**
- redness, flat, vulva, 68
- resistance
 antibacterials, 39
 bacteria, 162
 beta-lactam antibiotics, 39
- rhagades, in vulvitis, 66, **67**
- Rhodotorula rubra*, 8
- ribavirin, 47
- rifamycins, 45–46
- rod bacteria, 7
- rotavirus infection, in pregnancy, 188
- roundworm, 234
- rubella
 congenital infection, diagnosis, 172, **173**
 historical facts, 171
 period of infectiousness, **171**
 in pregnancy, 169–172
 clinical picture, 171
 diagnosis, 171–172

- effects of hyperimmune globulin, 173, 174
 level and types of damage, **172**
 prophylaxis, 173
 prenatal diagnosis, 172
 prophylaxis before pregnancy, 172–173
 vaccination, 173
 rubella, in pregnancy, 187–188
Rubulavirus, 188
 rupture of fetal membranes, premature, 212–214
- S**
- Sabin–Feldman test (SFT), 200
Saccharomyces cerevisiae, 8
Salmonella, 6, 16
Salmonella enterica, 204
 salmonella infection, in pregnancy, 204–205
 salpingitis, 148–153
 acute, 149–151
 clinical picture, 150
 diagnosis, 150–151
 without pathogen detection, 151
 pathogenesis, 149
 pathogens, 148–149
 risks/sequelae, 150
 therapy, 151
 subacute, 151–153
 clinical picture, 152
 diagnosis, 152
 laparoscopy, 152
 without pathogen detection, 152–153
 pathogenesis, 151–152
 pathogens, 151
 therapy, 153
 sarcoidosis, and chronic mastitis in pregnancy, **230**, 230–231
Sarcoptes scabiei hominis, 107
 scabies, 107, **107**
 scarlet fever, in pregnancy, 203–204
Schistosoma hematobium, 236, **236**
 schistosomiasis, 236, **236**
 self-inflicted infections, 238, **238**
 senile vaginitis, 128, **128**
 sepsis, 23, 156–158
 clinical picture, 157
 definition and course, 156–157
 diagnosis, 158
 pathogenesis, 157
 pathogens, 157
 puerperal, 218–220, **219**
 sequelae, 158
 therapy, 158
 septic miscarriage, 222–223
 septic shock, 158–159
 serological detection, 29–30
 antibodies, 22
 methods, 31–34
 serology, and *Candida* infection, 28
Serratia, 6
 sexually transmitted infections, 232–233
 definition, 232
 differential diagnosis, 232
 forms, 232–233
Shigella, 6
 shingles, in pregnancy, 186–187, **187**
 signs of infection, 53–63
 sites of action, antibacterials, 38
 skin
 bacteria, 12
 and vaginitis, 127
 care, anogenital region, 69
 disinfection, 239
 whitening, vulva, 68
 small pelvis, thrombophlebitis, 156
 solid-phase erythrocyte aggregation test, 32
 specimen collection
 fungi, 26
 viruses, 25
 staphylococci, 12, 15
 resistances, 162
Staphylococcus aureus, 6, 15
 and amniotic infection syndrome, 214
 in childbed infections, 217
 and dermatitis of mammillae, 229, **230**
 in factitious vulvitis, **238**
 furuncle/carbuncle, **77**, 78, **78**, **79**
 infections, 76, **77**, 78
 and inflammatory conglomerate tumor, 153
 and mastitis, 226
 and postoperative wound infection, 154
 and puerperal mastitis, 224
 and pyometra, 148
 and salpingitis, 150
 and septic shock, 158, 159
 and subacute salpingitis, 151
 and toxic shock syndrome, 159
 and tubo-ovarian abscess, 153, 154
 vaginitis, 112, 122, **123**
 vulvitis, **67**
Staphylococcus epidermidis, 6, 15
 and hidradenitis suppurativa, 104
Staphylococcus saprophyticus, 6
 streptococci, 6, 7
 and erysipelas, 81, **82**
 group A, 13–14
 and cervicitis, 140, **140**
 and impetigo contagiosa, 81
 infections, 78–81, **80–81**
 and inflammatory conglomerate tumor, 154
 and postoperative wound infection, 154
 in pregnancy, 203–204
 and salpingitis, 149
 and tubo-ovarian abscess, 154
 vaginitis, 120, **121–122**, 122
 group B (GBS), 14
 infection in pregnancy, 205–207, **206**
 prophylaxis in pregnancy, 207
 resistances, 162
 group D, 14
 group G, 14
 milleri group, 14
 and subacute salpingitis, 151
Streptococcus agalactiae, 205
Streptococcus pneumoniae, 14–15
Streptococcus pyogenes, 13, 14
Strongyloides stercoralis, 236
 strongyloidiasis, 236, **236**
 sulfonamides, 45
 surgery, and wound infection, **154**, 154–155
 swab collection, 22
 sweat glands, 104
 symptoms of infection
 local, 53
 systemic, 53–54
 syphilids, macular, **102**
 syphilis, 100–103, **101–103**, 232
 vs. Behçet syndrome, 108
 cardiovascular, 101
 clinical picture, 101
 diagnosis, 102
 latent, 101
 in pregnancy, 193–195
 primary, 101, **101**
 cervix, 139–140, **140**
 secondary, 101, **102**
 tertiary, 101
 therapy, 102–103
 and vulvitis, **67**
- T**
- Taenia saginata*, 234
 tapeworms, 234–235
 Taq polymerase, 35
 teratogenicity, aciclovir, 180
 tetracyclines, 42
 resistances, 162
 thrombocytopenia, 55
 thrombophlebitis
 ovarian vein, 221
 small pelvis, 156
 tinea lingualis, 75–76
 titer levels, in serology, 31
 tonsillitis, in pregnancy, 203
Torulopsis glabrata, 75, 114, **114**
 toxic shock syndrome (TSS), 159–160
 clinical picture, 159
 diagnosis, 159–160
 pathogenesis, 159
 therapy, 160
Toxoplasma gondii, 198, 199, 200
 detection, 29
 toxoplasmosis, 50
 clinical picture, 198–199
 in pregnancy, 198–202, **199**
 diagnosis, 200–201, **201**
 prenatal diagnosis, 200–202
 therapy, 199–200, 202
 trachoma, and *Chlamydia trachomatis*, 133
 transport medium
 bacteria, 23–24
 and fungi, 26
 viruses, 25
Trponema pallidum hemagglutination test (TPHA), 102, 193, 195
 triazoles, 49
 trichomonads, **119**
Trichomonas vaginalis, detection, 29, **30**
 trichomoniasis
 chronic recurrent, 119
 in pregnancy, 215, **215**
 vagina, 116–119, **117–119**
 clinical picture, 116–117, **117**
 diagnosis, 117, **117**
 treatment, 118–119
Trichophyton rubrum, 75, **76**
Trichosporon cutaneum, 8
Trichuris trichiura, 234
Trichophyton rubrum, 8
 tubercle bacilli, and endometritis, 148
 tuberculin test, 166
 tuberculosis, 165–167
 genital, 165–166, **166**
 and infection risk for newborn, 223
 tuberculous mastitis, 226
 tubes, *see* salpingitis
 tubo-ovarian abscess, 153–154
 diagnosis, 154
 pathogenesis, 153
 pathogens, 154
 therapy, 154
 tumor
 and high-risk HPV types, 97
see also carcinoma; conglomerate tumor

- U**
- ulcer, venereal, 233
 - ulceration, vagina, 129, **129**
 - ulcers
 - with red halo, in genital herpes, 83, **85**
 - vulva, 108, **108**
 - umbilical blood, pathogen detection, 37
 - Ureaplasma urealyticum*, 5, 127
 - ureidopenicillins, 40
 - urethritis, 161
 - urinary diversion, 240
 - urinary tract infections (UTIs), 23, 160–164
 - complicated, 164
 - diagnosis, 164
 - pathogens, 164
 - therapy, 164
 - etiology, 161
 - frequency, 161
 - lower, 161–163
 - pathogens, 162
 - resistances, 162
 - upper, 163
 - urine analysis, 23
 - urosepsis, 161
- V**
- vaccination
 - HPV, 99
 - during pregnancy, 243
 - recommendations, 244
 - tuberculosis, newborns, 242–243
 - vaccines, 243–245
 - inactivated, 245
 - live, 245
 - nonresponders, 243
 - vagina
 - bacterial species, 11
 - diagnostic guide, infections, **112**
 - genital herpes, 115, **115**
 - HPV infection, 115–116, **116**
 - infections, 112–130
 - mycoplasma, 126–127
 - papillomatosis, 116
 - pathogen detection, 216
 - postoperative infection, 155
 - trichomoniasis, 116–119
 - ulceration, 129, **129**
 - vaginal flora, and premature deliveries, 210
 - vaginal stump, infection after hysterectomy, 155
 - vaginitis, 112–130
 - atrophic, 128, **128**, **129**
 - bacterial, 122
 - Candida albicans*, 112, **113**, 113–115, **114**
 - caused by protozoa, 116–122
 - discharge, 112
 - erosive, 128, **129**
 - fungal, 113–115
 - granular, 129–130
 - group A streptococci, 120, **121–122**, 122
 - intestinal bacteria, 127
 - other causes, 127–130
 - without pathogens, 127
 - plasma cell, 119–120, **120–121**
 - senile, 128, **128**
 - skin bacteria, 127
 - Staphylococcus aureus*, 122, **123**
 - viral, 115–116
 - vaginosis, bacterial, 122–126, **124–125**
 - in pregnancy, 207–208
 - valaciclovir, 47
 - varicella, in pregnancy, **184**, 184–186, **185**, **186**
 - clinical picture, 185
 - prophylaxis, 186
 - therapy, 185–186
 - varicella-zoster virus, 91
 - Veillonella parvula*, 6
 - Venereal Disease Research Laboratory (VDRL) test, 102
 - venereal ulcer, 233
 - venipuncture, 239
 - venous catheter, maintenance, 239
 - vesicles, opaque, in genital herpes, 83, **85**, **87**, **88**
 - vestibular adenitis, 92, **93**
 - vestibulitis, 92, **93**
 - viral infections
 - chemoprophylaxis, 241
 - immunoprophylaxis, 241
 - in pregnancy, 169–193, **170**
 - virostatics, 47–48
 - virulence, 2
 - mechanisms, urinary tract infections, 161
 - viruses, 2
 - detection, 25
 - sexually transmitted, 130
 - structures and sizes, 2, **3**
 - vulva
 - biopsy, 58, 61–62, **62–63**
 - carcinoma, 108, **109**
 - diagnostic guide, infections, **112**
 - disease groups, 68
 - exanthema, drug eruption, **110**
 - herpes zoster, 91, **92**
 - injuries/hematomas, 111, **111**
 - molluscum contagiosum, 91, **91**
 - pemphigus vulgaris, 111
 - psoriasis vulgaris, 111, **111**
 - schistosomiasis, 236, **236**
 - swelling, genital herpes, 83, **84**
 - treatment options, local, 69
 - ulcers, 108, **108**
 - vulvitis, 66–112
 - bacterial, 76–82
 - chronic severe, 70, **72**
 - differential diagnosis, 76, 78
 - dry, in candidiasis, 70, **71**
 - factitious, 238, **238**
 - with flaky discharge, in candidiasis, 69, **70**
 - fungal, 69–76
 - group A streptococci, 78–81, **80–81**
 - irritable, 109, **110**
 - with nodules, in candidiasis, **69**, **70**
 - other forms, 92–112
 - without pain, 93–94
 - pathogenesis, 66, **67**
 - plasma cell, 92, **93**
 - with pustules, in candidiasis, 69, 70, **71**
 - rhagades, 66, **67**
 - viral, 82–91
 - white nodules, in candidiasis, 70, **71**
 - vulvovaginitis, recurrent, **80**

W

 - warts, genital, *see* genital warts
 - water birth, and infection risk, 223
 - Western blot, 34
 - whipworm, 234
 - whitening, of skin, vulva, 68
 - whooping cough, in pregnancy, 204
 - worm species, 234
 - wound care, 240
 - wound drainage, 240
 - wound healing, disturbed, after cesarean section, 221–222, **222**
 - wound infection
 - after surgery, **154**, 154–155
 - episiotomy, **208**
 - puerperal, 220–221

Y

 - yeasts, 4, 7
 - detection, 25–26
 - occurrence and clinical significance, 8
 - in vaginitis, 114–115
 - yellow secretion, in chlamydial cervicitis, **131**, **136**
 - Yersinia*, 16
 - and arthritis, 237

Z

 - zidovudine, 47